TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients

We investigated the hypothesis that the varying treatment efficacy of adjuvant 5-fluorouracil (5FU) in stage III colon cancer is linked to the TP53 mutational status. ABCSG-90 was a prospective randomized trial in which effect of adjuvant 5FU was studied in stage III colon cancer patients. Tumor mat...

Full description

Bibliographic Details
Main Authors: Daniela Kandioler, Martina Mittlböck, Sonja Kappel, Harald Puhalla, Friedrich Herbst, Cord Langner, Brigitte Wolf, Jörg Tschmelitsch, Walter Schippinger, Günther Steger, Friedrich Hofbauer, Hellmut Samonigg, Michael Gnant, Bela Teleky, Irene Kührer
Format: Article
Language:English
Published: Elsevier 2015-08-01
Series:EBioMedicine
Subjects:
TP53
Predictive biomarker
Stage III colon cancer
Adjuvant 5-fluorouracil
Varying treatment efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396415300359

Internet

http://www.sciencedirect.com/science/article/pii/S2352396415300359

Similar Items